RESUMO

This review focuses on proteins and peptides with antimicrobial activity because these biopolymers can be useful in the fight against infectious diseases and to overcome the critical problem of microbial resistance to antibiotics. In fact, snakes show the highest diversification among reptiles, surviving in various environments; their innate immunity is similar to mammals and the response of their plasma to bacteria and fungi has been explored mainly in ecological studies. Snake venoms are a rich source of components that have a variety of biological functions. Among them are proteins like lectins, metalloproteinases, serine proteinases, L-amino acid oxidases, phospholipases type A2, cysteine-rich secretory proteins, as well as many oligopeptides, such as waprins, cardiotoxins, cathelicidins, and ß-defensins. In vitro, these biomolecules were shown to be active against bacteria, fungi, parasites, and viruses that are pathogenic to humans. Not only cathelicidins, but all other proteins and oligopeptides from snake venom have been proteolyzed to provide short antimicrobial peptides, or for use as templates for developing a variety of short unnatural sequences based on their structures. In addition to organizing and discussing an expressive amount of information, this review also describes new ß-defensin sequences of Sistrurus miliarius that can lead to novel peptide-based antimicrobial agents, using a multidisciplinary approach that includes sequence phylogeny.

RESUMO

This review focuses on proteins and peptides with antimicrobial activity because these biopolymers can be useful in the fight against infectious diseases and to overcome the critical problem of microbial resistance to antibiotics. In fact, snakes show the highest diversification among reptiles, surviving in various environments; their innate immunity is similar to mammals and the response of their plasma to bacteria and fungi has been explored mainly in ecological studies. Snake venoms are a rich source of components that have a variety of biological functions. Among them are proteins like lectins, metalloproteinases, serine proteinases, L-amino acid oxidases, phospholipases type A2, cysteine-rich secretory proteins, as well as many oligopeptides, such as waprins, cardiotoxins, cathelicidins, and β-defensins. In vitro, these biomolecules were shown to be active against bacteria, fungi, parasites, and viruses that are pathogenic to humans. Not only cathelicidins, but all other proteins and oligopeptides from snake venom have been proteolyzed to provide short antimicrobial peptides, or for use as templates for developing a variety of short unnatural sequences based on their structures. In addition to organizing and discussing an expressive amount of information, this review also describes new β-defensin sequences of Sistrurus miliarius that can lead to novel peptide-based antimicrobial agents, using a multidisciplinary approach that includes sequence phylogeny.

RESUMO

Bitis arietans is a medical importance snake found predominantly in sub-Saharan Africa. The envenomation is characterized by local and systemic reactions, which can lead the victims to death or permanent disabilities. However, the lack of antivenoms makes the treatment worse. Therefore, the present work aimed to identify venom toxins, learn about their properties and develop antitoxins. The F2 fraction obtained from affinity chromatography fractionation of B. arietans venom showed the major proteolytic activity of SVMPs from enzymatic tests. Based on mass spectrometry analysis, 57 different peptides were identified in the F2 fraction. Among the most prevalent peptides are SVMPs. ELISA titration assays performed together with the mouse immunization step (BALB/c) demonstrated the development of anti-F2 fraction antibodies by the animals. The determination of the affinity of antibodies against different Bitis venoms was evaluated, revealing that only the B. arietans venom has peptides recognized by anti-F2 fraction antibodies. In vivo analyzes demonstrated the hemorrhagic capacity of the venom, the effectiveness of the antibodies to inhibit up to 80% of hemorrhage and 0% of the lethality caused by the venom. Taken together, the data indicate: 1) the prevalence of peptides that influence hemostasis and the dissemination of local and systemic effects caused by poisoning; 2) the effectiveness of monospecific antibodies in inhibiting specific activities of the venom; and 3) the isolation of toxins, production and characterization of antibodies is a crucial step in the development of new antivenoms. Therefore, the obtained results help in understanding the mechanism involved in the envenomation and can be useful for the study of new complementary therapies to antivenom in the treatment of accidents by Bitis arietans.

Bitis arietans é uma serpente de importância médica encontrada predominantemente na África Subsaariana. O envenenamento é caracterizado por efeitos locais e sistêmicos, que podem levar a morte ou incapacidades permanentes. No entanto, a carência de antivenenos agravam o tratamento. Portanto, este trabalho teve como objetivo identificar toxinas do veneno, conhecer suas propriedades e desenvolver antitoxinas. A fração F2 obtida do fracionamento por cromatografia de afinidade do veneno de B. arietans, demonstrou a atividade proteolítica majoritária de SVMPs a partir de testes enzimáticos. Com base na análise por espectrometria de massas, foram identificados 57 peptídeos diferentes na fração F2. Entre os peptídeos de maior prevalência estão as SVMPs. Ensaios de titulação por ELISA realizados em conjunto à etapa de imunização de camundongos (BALB/c), demonstraram o desenvolvimento de anticorpos anti-fração F2 pelos animais. A determinação da afinidade dos anticorpos contra diferentes venenos de Bitis foi avaliada, revelando que somente o veneno de B. arietans possui peptídeos reconhecidos pelos anticorpos anti-fração F2. Análises in vivo demonstraram a capacidade hemorrágica do veneno, a eficácia dos anticorpos de inibir em até 80% a hemorragia e em 0% da letalidade causadas pelo veneno. Em conjunto, os dados indicam: 1) a prevalência de peptídeos que atuam influenciando na hemostasia e na disseminação de efeitos locais e sistêmicos causados pelo envenenamento; 2) a eficácia de anticorpos monoespecíficos em inibir atividades específicas do veneno; e 3) o isolamento de toxinas, produção e caracterização de anticorpos é uma etapa crucial no desenvolvimento de novos antivenenos. Desta forma, os resultados obtidos auxiliam na compreensão no mecanismo de envenenamento e podem ser úteis para o estudo de novas terapias complementares ao antiveneno no tratamento dos acidentes por Bitis arietans.

RESUMO

BACKGROUND: Resistance to apoptosis in chronic myeloid leukemia (CML) is associated with constitutive tyrosine kinase activity of the Bcr-Abl oncoprotein. The deregulated expression of apoptosis-related genes and alteration in epigenetic machinery may also contribute to apoptosis resistance in CML. Tyrosine kinase inhibitors target the Bcr-Abl oncoprotein and are used in CML treatment. The resistance of CML patients to tyrosine kinase inhibitors has guided the search for new compounds that may induce apoptosis in Bcr-Abl+ leukemic cells and improve the disease treatment. METHODS: In the present study, we investigated whether the L-amino acid oxidase isolated from Bothrops moojeni snake venom (BmooLAAO-I) (i) was cytotoxic to Bcr-Abl+ cell lines (HL-60.Bcr-Abl, K562-S, and K562-R), HL-60 (acute promyelocytic leukemia) cells, the non-tumor cell line HEK-293, and peripheral blood mononuclear cells (PBMC); and (ii) affected epigenetic mechanisms, including DNA methylation and microRNAs expression in vitro. RESULTS: BmooLAAO-I induced ROS production, apoptosis, and differential DNA methylation pattern of regulatory apoptosis genes. The toxin upregulated expression of the pro-apoptotic genes BID and FADD and downregulated DFFA expression in leukemic cell lines, as well as increased miR-16 expression - whose major predicted target is the anti-apoptotic gene BCL2 - in Bcr-Abl+ cells. CONCLUSION: BmooLAAO-I exerts selective antitumor action mediated by H2O2 release and induces apoptosis, and alterations in epigenetic mechanisms. These results support future investigations on the effect of BmooLAAO-I on in vivo models to determine its potential in CML therapy.

RESUMO

Resistance to apoptosis in chronic myeloid leukemia (CML) is associated with constitutive tyrosine kinase activity of the Bcr-Abl oncoprotein. The deregulated expression of apoptosis-related genes and alteration in epigenetic machinery may also contribute to apoptosis resistance in CML. Tyrosine kinase inhibitors target the Bcr-Abl oncoprotein and are used in CML treatment. The resistance of CML patients to tyrosine kinase inhibitors has guided the search for new compounds that may induce apoptosis in Bcr-Abl+ leukemic cells and improve the disease treatment. Methods: In the present study, we investigated whether the L-amino acid oxidase isolated from Bothrops moojeni snake venom (BmooLAAO-I) (i) was cytotoxic to Bcr-Abl+ cell lines (HL-60.Bcr-Abl, K562-S, and K562-R), HL-60 (acute promyelocytic leukemia) cells, the non-tumor cell line HEK-293, and peripheral blood mononuclear cells (PBMC); and (ii) affected epigenetic mechanisms, including DNA methylation and microRNAs expression in vitro. Results: BmooLAAO-I induced ROS production, apoptosis, and differential DNA methylation pattern of regulatory apoptosis genes. The toxin upregulated expression of the pro-apoptotic genes BID and FADD and downregulated DFFA expression in leukemic cell lines, as well as increased miR-16 expression - whose major predicted target is the anti-apoptotic gene BCL2 - in Bcr-Abl+ cells. Conclusion: BmooLAAO-I exerts selective antitumor action mediated by H2O2 release and induces apoptosis, and alterations in epigenetic mechanisms. These results support future investigations on the effect of BmooLAAO-I on in vivo models to determine its potential in CML therapy.(AU)

Assuntos

RESUMO

Resistance to apoptosis in chronic myeloid leukemia (CML) is associated with constitutive tyrosine kinase activity of the Bcr-Abl oncoprotein. The deregulated expression of apoptosis-related genes and alteration in epigenetic machinery may also contribute to apoptosis resistance in CML. Tyrosine kinase inhibitors target the Bcr-Abl oncoprotein and are used in CML treatment. The resistance of CML patients to tyrosine kinase inhibitors has guided the search for new compounds that may induce apoptosis in Bcr-Abl+ leukemic cells and improve the disease treatment. Methods: In the present study, we investigated whether the L-amino acid oxidase isolated from Bothrops moojeni snake venom (BmooLAAO-I) (i) was cytotoxic to Bcr-Abl+ cell lines (HL-60.Bcr-Abl, K562-S, and K562-R), HL-60 (acute promyelocytic leukemia) cells, the non-tumor cell line HEK-293, and peripheral blood mononuclear cells (PBMC); and (ii) affected epigenetic mechanisms, including DNA methylation and microRNAs expression in vitro. Results: BmooLAAO-I induced ROS production, apoptosis, and differential DNA methylation pattern of regulatory apoptosis genes. The toxin upregulated expression of the pro-apoptotic genes BID and FADD and downregulated DFFA expression in leukemic cell lines, as well as increased miR-16 expression - whose major predicted target is the anti-apoptotic gene BCL2 - in Bcr-Abl+ cells. Conclusion: BmooLAAO-I exerts selective antitumor action mediated by H2O2 release and induces apoptosis, and alterations in epigenetic mechanisms. These results support future investigations on the effect of BmooLAAO-I on in vivo models to determine its potential in CML therapy.(AU)

Assuntos

RESUMO

Snake venoms are rich sources of active proteins that have been employed in the diagnosis and treatment of health disorders and antivenom therapy. Developing countries demand fast economical downstream processes for the purification of this biomolecule type without requiring sophisticated equipment. We developed an alternative, simple and easy to scale-up method, able to purify simultaneously protease and phospholipase A2 toxins from Bothrops alternatus venom. It comprises a multiple-step partition procedure with polyethylene-glycol/phosphate aqueous two-phase systems followed by a gel filtration chromatographic step. Two single bands in SDS-polyacrylamide gel electrophoresis and increased proteolytic and phospholipase A2 specific activities evidence the homogeneity of the isolated proteins.(AU)

Assuntos

RESUMO

Snake venoms are rich sources of active proteins that have been employed in the diagnosis and treatment of health disorders and antivenom therapy. Developing countries demand fast economical downstream processes for the purification of this biomolecule type without requiring sophisticated equipment. We developed an alternative, simple and easy to scale-up method, able to purify simultaneously protease and phospholipase A2 toxins from Bothrops alternatus venom. It comprises a multiple-step partition procedure with polyethylene-glycol/phosphate aqueous two-phase systems followed by a gel filtration chromatographic step. Two single bands in SDS-polyacrylamide gel electrophoresis and increased proteolytic and phospholipase A2 specific activities evidence the homogeneity of the isolated proteins.

Assuntos

RESUMO

Los venenos de animales son mezclas complejas de proteínas, péptidos, enzimas y trazas de elementosno proteicos tales como carbohidratos y sales, cuya finalidad es inmovilizar la presa ycomenzar a digerirla; algunos de estos compuestos han sido aislados y caracterizados o descritoscomo toxinas letales, o se les han atribuido acciones potentes sobre proteínas específicas como, porejemplo, las involucradas en la coagulación sanguínea. Debido al descubrimiento en 1971 del péptidoque dio origen al captopril y al entendimiento de los efectos potenciales de las toxinas, se empezó aconsiderar que los venenos de animales son fuentes ricas en compuestos bioactivos, que no soloproporcionan las herramientas necesarias para descifrar los detalles moleculares de diversos procesosfisiológicos, sino que también sirven como fuente de inspiración para diseñar y desarrollaragentes terapéuticos. Este artículo expone la aplicación de nuevas alternativas terapéuticas y demodelos para el diseño de las mismas basados en algunas moléculas aisladas de venenos de serpientescon alto potencial en campos como la biomedicina y la farmacia.

Animal venoms are complex mixtures of proteins, peptides, enzymes and trace elements such ascarbohydrates and salts, which serve to immobilize preys and to begin their digestion. Some ofthese compounds have been isolated and characterized, or described as lethal toxins, while othershave powerful actions on specific proteins, such as those involved in blood coagulation. Due to thediscovery in 1971 of the peptide that gave rise to captopril and to a better understanding of thepotential effects of toxins, animal venoms started to be considered as rich sources of bioactive compounds, which not only provide the necessary toolsto decipher molecular details of various physiologicalprocesses, but also are a source of inspiration to designand develop a range of new therapeutic agents. Thisreview presents the application of new therapeuticoptions or models to design them based on certainmolecules isolated from snake venoms, with highpotential in fields such as biomedicine and pharmacy.

Assuntos